The molecular basis of lethal prostate cancer
The goal of the Hurley laboratory is to reduce the death and suffering caused by aggressive prostate cancer. To this end, the laboratory is focused on identifying novel genetic and molecular pathways driving lethal prostate cancer. We recently identified SPARCL1 as a gene down-regulated in high-grade/ metastatic prostate cancer that is a significant, independent prognostic marker of disease progression to metastases. The laboratory is currently examining the mechanistic roles of SPARCL1 and other mediators of aggressive prostate cancer. In addition, the laboratory is also developing new methods for the early identification of drug resistance in metastatic patients using plasma tumor DNA and next generation technologies.
|2004||Ph.D./University of Chicago School of Medicine||Cancer Biology|
|2009||Post-Doctoral Fellowship/The Johns Hopkins School||Radiation Oncology|
2003 HCT-Chk2-/-p53-/- genetically engineered isogenic cell lines.
Johns Hopkins Technology Transfer Reference Number C10803
2012 SPARCL1 and Metastatic Prostate Cancer.
Johns Hopkins Technology Transfer Reference Number C12106
2013 ASPN and Metastatic Prostate Cancer.
Johns Hopkins Technology Transfer Reference Number C12091
2014 Johns Hopkins Prostate Research Day Award, Johns Hopkins University
2013 Multi-Institutional Prostate SPORE meeting Poster Award – Fort Lauderdale, FL
2012 Johns Hopkins Cancer Research Day Award, Johns Hopkins University
2003 IBD Retreat Research Talk Award, University of Chicago
1997 Graduated Magna Cum Laude in academics, Lawrence University
1997 Graduated Magna Cum Laude in research, Lawrence University
1997 Phi Beta Kappa, Lawrence University